| | PRDM2mRNA levels | | |
|---|
Feature | High* | Low | Chi-square | p-Value |
|---|
All cases | 12 | 12 | | |
Patient’s age | | | | |
≥50 | 5 | 6 | 0.168 | 0.682 |
<50 | 7 | 6 | | |
Patient’s gender | | | | |
Male | 9 | 7 | 0.756 | 0.385 |
Female | 3 | 5 | | |
Serum PRL levels | | | | |
≥435 μg/ml ** | 4 | 5 | 0.178 | 0.673 |
<435 μg/ml | 8 | 7 | | |
Tumor size | | | | |
≥2 cm | 5 | 7 | 0.670 | 0.413 |
<2 cm | 7 | 5 | | |
Recurrence*** | | | | |
Yes | 4 | 10 | 6.511 | 0.011 |
No | 8 | 2 | | |
Resistance to BRC**** | | | | |
| | 4 | 9 | 4.332 | 0.037 |
| | 8 | 3 | | |
- *The median expression level was used as the cutoff. Low PRDM2 mRNA levels were defined as values below the 50th percentile of the 12 patients; values at or above the 50th percentile were classified as high levels.
- **The median serum PRL level was used as the cutoff: 435 μg/ml. Low serum PRL levels were defined as values below the 50th percentile of the 12 patients; values at or above the 50th percentile were classified as high levels.
- ***Recurrence was defined as the discovery of an elevated PRL level at any time in the postoperative surveillance period after an initial remission.
- ****Resistant tumors to BRC were defined as those from patients whose serum PRL levels remained abnormally high after at least 3 months of treatment with a daily dose of 15 mg BRC.
